Recent study at UC Irvine found that semaglutide medication may benefit 93 million U.S. adults

  • Publication date August 15, 2023
  • Categories: News
Estimated 10-Year Cardiovascular Disease Risk and Projected Number of Cardiovascular Events (in Millions) in 10 Years Without and With Semaglutide Treatment, Among US Adults without Cardiovascular Disease but with Overweight or Obesity. Data adapted from Wong ND et al., Cardiovasc Drug Ther 2023.

Researchers from the University of California, Irvine, have just published a study that projects 93 million U.S. adults who are overweight and obese may be suitable for the 2.4 mg dosage of semaglutide, a weight loss medication known under the brand name Wegovy.

Read Story